A Phase II Study of Fruquintinib in Combination with Gefitinib in Stage IIIb/IV NSCLC Patients Harboring EGFR Activating Mutations

被引：1
|
作者：
Lu, S. [1 ]
Zhou, J. [2 ]
Niu, X. [3 ]
Chen, M. [4 ]
Hua, Y. [4 ]
Su, W. [4 ]
机构：
[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Sch Med, Shanghai, Peoples R China
[2] Zhejiang Univ, Coll Med, Affiliated Hosp 1, Hangzhou, Zhejiang, Peoples R China
[3] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Shanghai, Peoples R China
[4] Hutchison Medipharma, Shanghai, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 11期
关键词：
Fruquintinib; non-small cell lung cancer; gefitinib;
D O I：
10.1016/j.jtho.2017.09.301
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
JCES 01.12
引用
收藏
页码：S1735 / S1735
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study
    Ma, Yuxiang
    Chen, Qun
    Zhang, Yang
    Xue, Jinhui
    Liu, Qianwen
    Zhao, Yuanyuan
    Yang, Yunpeng
    Huang, Yan
    Fang, Wenfeng
    Hou, Zhiguo
    Li, Shaorong
    Wang, Jing
    Zhang, Li
    Zhao, Hongyun
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2023, 92 (05) : 411 - 418
  • [32] Pharmacokinetics, safety, tolerability, and feasibility of apatinib in combination with gefitinib in stage IIIB-IV EGFR-mutated non-squamous NSCLC: a drug-drug interaction study
    Yuxiang Ma
    Qun Chen
    Yang Zhang
    Jinhui Xue
    Qianwen Liu
    Yuanyuan Zhao
    Yunpeng Yang
    Yan Huang
    Wenfeng Fang
    Zhiguo Hou
    Shaorong Li
    Jing Wang
    Li Zhang
    Hongyun Zhao
    Cancer Chemotherapy and Pharmacology, 2023, 92 : 411 - 418
  • [33] Sintilimab in Combination with Anlotinib in NSCLC Patients with Uncommon EGFR Mutations: A Phase II, Single-arm, Prospective Study
    Fan, Y.
    Chen, K.
    Xu, Y.
    Huang, Z.
    Hong, W.
    Li, H.
    Xie, F.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S352 - S352
  • [34] Phase 2 trial of talabostat and docetaxel in patients with stage IIIb/IV NSCLC.
    Cunningham, C
    Richards, D
    Salgia, R
    Leonard, R
    Raju, R
    Arseneau, J
    Packer, S
    Gregoire, L
    Haltom, L
    Uprichard, MJ
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 650S - 650S
  • [35] Interleukin-6 Is a Valuable Predictive Marker for Therapeutic Effect of Gefitinib in Patients with Advanced NSCLC Harboring EGFR Mutations
    Kato, Yuka
    Hotta, Katsuyuki
    Tamura, Tomoki
    Tanaka, Takehiro
    Ichimura, Koichi
    Ohashi, Kadoaki
    Kubo, Toshio
    Ichihara, Eiki
    Tanimoto, Mitsune
    Kiura, Katsuyuki
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S646 - S647
  • [36] Clinical outcomes of 1st-line gefitinib for patients with advanced NSCLC harboring EGFR mutations and poor PS
    Miura, Yosuke
    Minato, Koichi
    Fujimoto, Sakae
    Sunaga, Noriaki
    Yamada, Masanobu
    ANNALS OF ONCOLOGY, 2015, 26 : 136 - 136
  • [37] Histological analysis in pemetrexed treated patients with stage IIIB/IV NSCLC: results from an open label randomized phase II study
    Niho, Seiji
    Kubota, Kaoru
    Enatsu, Sotaro
    Nambu, Yoshihiro
    Nishiwaki, Yutaka
    Saijo, Nagahiro
    Fukuoka, Masahiro
    JOURNAL OF THORACIC ONCOLOGY, 2009, 4 (09) : S533 - S533
  • [38] Combination of the S49076 with gefitinib in NSCLC patients progressing on EGFR-TKI and harboring MET/AXL dysregulation
    Viteri, S.
    Chang, G-C.
    Chiari, R.
    Cho, B. C.
    Ciardiello, F.
    Curigliano, G.
    Hida, T.
    Lee, D. H.
    Lim, W. T. D.
    Lin, C-C.
    Martinez, A.
    Murakami, H.
    Natsume, I.
    Nishio, M.
    Paz-Ares, L.
    Soo, R. A.
    Cattan, V.
    Gandossi, E.
    Heck, H.
    Park, K.
    ANNALS OF ONCOLOGY, 2018, 29
  • [39] Combination of Metformin and Gefitinib as First-Line Therapy for Nondiabetic Advanced NSCLC Patients with EGFR Mutations: A Randomized, Double-Blind Phase II Trial
    Li, Li
    Jiang, Liyan
    Wang, Yubo
    Zhao, Yizhuo
    Zhang, Xiao-Ju
    Wu, Guoming
    Zhou, Xiangdong
    Sun, Jianguo
    Bai, Jun
    Ren, Biyong
    Tian, Kun
    Xu, Zhi
    Xiao, Hua-liang
    Zhou, Qi
    Han, Rui
    Chen, Hengyi
    Wang, Haidong
    Yang, Zhenzhou
    Gao, Chan
    Cai, Shangli
    He, Yong
    CLINICAL CANCER RESEARCH, 2019, 25 (23) : 6967 - 6975
  • [40] Epirubicine/gemcitabine combination in stage IIIb-IV non small cell lung cancer (NSCLC). Preliminary data of a phase I/II study
    Illiano, A.
    Battiloro, C.
    Rocco, D.
    Formato, R.
    Iaffaioli, R., V
    ANNALS OF ONCOLOGY, 2006, 17 : XI23 - XI23
12345